Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment

被引:0
|
作者
Francesco Cianci
Angelo Zoli
Elisa Gremese
Gianfranco Ferraccioli
机构
[1] Istituto di Reumatologia e Scienze Affini,
[2] Università Cattolica del Sacro Cuore,undefined
[3] Institute of Rheumatology,undefined
[4] School of Medicine,undefined
[5] Catholic University of the Sacred Heart,undefined
来源
Clinical Rheumatology | 2017年 / 36卷
关键词
Biologic drugs; Hyperostosis; Osteitis; SAPHO; Skin; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare disease which is often misdiagnosed and under-recognized, because of its peculiar and heterogeneous clinical presentation. Its main features consist of cutaneous and osteoarticular manifestations, the latter affecting more often the anterior chest wall and having typical radiologic findings. There are no validated diagnostic criteria for SAPHO and no guidelines for treatment, due mainly to its rarity; as a consequence, therapy is empirical and aimed to control pain and modifying inflammatory process. To date, the use of anti-TNF agents has been proved to be a valid alternative for patients unresponsive to conventional treatments, such as NSAIDs, corticosteroids, DMARDs and biphosphonates. The clinical heterogeneity of the disease, possibly due to differences in pathogenic mechanism of different manifestations, is challenging for both diagnosis and treatment, which should aim to control both skin and bone involvement in different clinical subsets. Here, we summarize the current status of knowledge about the SAPHO syndrome and present two cases of patients with very different disease manifestations, suggesting the need for personalized treatment.
引用
收藏
页码:2151 / 2158
页数:7
相关论文
共 50 条
  • [21] Pamidronate: a novel treatment for the SAPHO syndrome?
    Marshall, H
    Bromilow, J
    Thomas, AL
    Arden, NK
    RHEUMATOLOGY, 2002, 41 (02) : 231 - U3
  • [22] Successful treatment of SAPHO syndrome with apremilast
    Adamo, S.
    Nilsson, J.
    Krebs, A.
    Steiner, U.
    Cozzio, A.
    French, L. E.
    Kolios, A. G. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 959 - 962
  • [23] Pamidronate in the treatment of childhood SAPHO syndrome
    Kerrison, C
    Davidson, JE
    Cleary, AG
    Beresford, MW
    RHEUMATOLOGY, 2004, 43 (10) : 1246 - 1251
  • [24] Efficacy of pamidronate in the treatment of SAPHO syndrome
    Sayag-Boukris, V
    Laoussadi, S
    Cormier, C
    Laroche, F
    Menkès, CJ
    Kahan, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S114 - S114
  • [25] Etanercept in the treatment of refractory SAPHO syndrome
    Zhang, Lei
    Gao, Zhaomeng
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 5 (04): : 62 - 66
  • [27] Efficacy of alendronate in the treatment of the SAPHO syndrome
    Fioravanti, Antonella
    Cantarini, Luca
    Burroni, Luca
    Mazzei, Maria Antonietta
    Volterrani, Luca
    Galeazzi, Mauro
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (03) : 183 - 184
  • [28] Clinical application of JAK inhibitors in SAPHO syndrome
    Wu, Guiying
    Wang, Cheng
    Wrriliga, Yong
    Wang, Yong
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (08)
  • [29] Challenging the opinion that SAPHO syndrome is associated with low intracellular ROS production in neutrophils
    P Wekell
    H Björnsdottir
    L Björkman
    M Sundqvist
    K Christenson
    V Osla
    S Berg
    A Fasth
    A Welin
    J Bylund
    A Karlsson
    Pediatric Rheumatology, 13 (Suppl 1)
  • [30] Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome - A challenging diagnosis not to be missed
    Zimmermann, Petra
    Curtis, Nigel
    JOURNAL OF INFECTION, 2016, 72 : S106 - S114